Anaplastic Large Cell Lymphoma
Vose, J. et al. Journal of Clinical Oncology 26(25): 4124-4130.
Vose, J., J. Armitage, et al. (2008). Journal of Clinical Oncology 26(25): 4124-4130.
Webb, T. R.et al. Expert Rev Anticancer Ther 9(3): 331-356.
de Leval, L. and P. Gaulard (2008). Hematology 2008(1): 272-279
Molecular network interacting with NPM-ALK.
-
80
33
56
71
30
-
93
37
68
90
40
Shiota, M et al. Blood 86(5): 1954-1960. Falini, B et al .Blood 93(8): 2697-2706. Gascoyne, R. D et al. Blood 93(11): 3913-3921. ten Berge, R. L., et al. Histopathology 43(5): 462-469.
Anaplastic Large Cell Lymphoma：间 变大细胞淋巴瘤
异型性是肿瘤组织和细胞出现成 熟障碍和分化障碍的表现。异型 性越大，成熟程度和分化程度就 越低。有些恶性肿瘤细胞分化很 差，异型性显著，称为间变性肿 瘤（ Anaplastic neoplasma）。间 变性的肿瘤细胞常就有多形性 （pleomorphism），即肿瘤细胞 的大小和形状变异很大。间变性 肿瘤多为高度恶性的肿瘤。
lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Kempf, W., K. Pfaltz, et al. (2011).Blood.Online
ALCL：形态特征
占70%
占5%-10%
占10%
de Leval, L et al. Hematology 2008(1): 272-279
临床及病理特点
Savage, K. J et al. Blood Reviews 21(4): 201-216.
临床及病理特点
primary cutaneous CD30-positive lymphoproliferative disorders: c-ALCL and lymphomatoid papulosis
Shiota etal
16
51
Falini et al
22 -
Gascoyne et al 30 61
Ten Berge et al 23 54
IPI（%HI-H） CR rate（%）
5-years survival
ALK+ ALK-
-
-
47 28
-
-
8
36
ALK+ 77 92
ALK- ALK+ ALK-
Savage, K. J et al. Blood Reviews 21(4): 201-216.
European Organization for Research and Treatment of Cancer (EORTC), International Society of Cutaneous Lymphoma (ISCL) and United States Cutaneous Lymphoma Consortium (USCLC) consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders:
病理学（第六版）人民卫生出版社。P96
Anaplastic Large Cell Lymphoma：间 变大细胞淋巴瘤
Anaplastic :间变
病理学（第六版）人民卫生出版社。P96
Chiarle, R., C. et al. (2008). Nat Rev Cancer 8(1): 11-23.
©2007 by American Society of Hematology
ALK and Ras–ERK ALK and STATs ALK and PI3K
Amin H M , Lai R Blood 2007;110:2259-2267
预后：
Median age （years）
ALK+ ALK-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) NCCN Version 3.2011
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) NCCN Version 3.2011
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) NCCN Version 3.2011
S-ALCL占成人NHL的2%-3%，儿童NHL的10-15%；分为ALK+ 与ALK-亚型
C-ALCL占皮肤淋巴瘤 的8%，男性多见
Fatusi, O.et al. Journal of Oral and Maxillofacial Surgery 68(4): 884-888. Querfeld, C. et al. Oncology (Williston Park) 24(7): 574-587
Lamant, L. et al. (2007). Blood 109(5): 2156-2164.
Jacobsen, E.. The Oncologist 11(7): 831-840.
临床及病理特点
Querfeld, C. et al. Oncology (Williston Park) 24(7): 574-587.